Developer docs
API playgroundTry for free, no card

Search company profiles

Kolosis BIO

Full company profile

uuid000acqm

Namestring
Kolosis BIO
Legal namestring
Kolosis BIO, LLC
Websiteurl
kolosis.com
Company typeenum
Private
Founded yearint
2019
Descriptiontext

Kolosis BIO is a privately held, pure-play surgical biologics company founded in 2019 and headquartered in Salt Lake City, Utah. The company commercializes a portfolio of allograft and synthetic bone grafts, extracellular matrices, and cardiac surgery products across three categories: orthobiologics, surgical incision management, and cardiac surgery. Its product lineup includes Kore Fiber, the DBX family (Putty, Mix, Fiber), Summit Matrix, Prime HD, APEXecm, ATLAS, and IKON, all sourced through an exclusive partnership with MTF Biologics, a nonprofit tissue processor whose proprietary aseptic processing preserves native collagen architecture, matrix proteins, and osteoinductive potential that terminal sterilization methods would damage.

Kolosis generates revenue by selling surgical biologics to hospitals and surgeons for use in spine fusion, orthopedic bone grafting, cardiac surgery, and wound care procedures. The go-to-market combines an enterprise field sales team with a network of over 400 independent distributors covering all 50 US states and Canada, with products approved in over 5,800 facilities through GPO and IDN contracts accessed via MTF Biologics. The company's 35,000+ fusion procedures over the trailing 12 months reflect established clinical adoption, supported by comparative preclinical data and a sales organization drawn heavily from NuVasive, Orthofix, Medtronic Spine and Biologics, and Globus Medical.

The business model is asset-light distribution of partner-processed tissue, with Kolosis focused on commercial execution, surgeon relationships, and product portfolio expansion rather than tissue processing R&D. Recent strategic activity includes three product launches within roughly 14 months (Summit Matrix in 2025, APEXecm and DBX Fiber in early 2026), entry into cardiac surgery and ECM wound management, and additions to the executive team including a CFO in 2025 and a Southeast AVP in 2026 to support continued national scale.

Short descriptiontext

Kolosis BIO is a privately held, pure-play surgical biologics company that commercializes allograft and synthetic bone grafts, extracellular matrices, and cardiac surgery products through an exclusive partnership with MTF Biologics, selling to hospitals and surgeons across spine, orthopedic, cardiac, and wound care procedures.

Operating statusenum
Operating
Ownership categoryenum
Headcount rangeband
11–50
akta.pro rankint
HeadquartersSalt Lake City, United States
HQ citystring
Salt Lake City
HQ countrystring
United States
HQ regionstring
North America
Markets served

Serves global market

Offices1 record

Each record includes

City, Country, Type, Description, Source

Keyword5 values
orthobiologics products, surgical bone grafts, allograft tissue matrices, spine biologics, cardiac surgery matrices
Industry4 codes
PRIMARYHLAHAEAG
Bone Graft Substitutes & Orthobiologics (Synthetic/Allograft/DBM)
Healthcare & Life Sciences/Medical Devices & Diagnostics/Implants & Prosthetics (Orthopedic/Neuro/Spine/Dental)
SECONDARYHLAAAGAH
Cartilage, Bone & Musculoskeletal Regeneration
Healthcare & Life Sciences/Biotechnology & Biologics/Regenerative Medicine & Tissue Engineering
SECONDARYHLAHALAE
Skin Substitutes & Biologic/Regenerative Wound Therapies (Matrices, Grafts)
Healthcare & Life Sciences/Medical Devices & Diagnostics/Wound Care, Ostomy & Continence Products
SECONDARYHLAAAGAG
Wound Healing & Skin Regeneration (advanced dressings, skin substitutes)
Healthcare & Life Sciences/Biotechnology & Biologics/Regenerative Medicine & Tissue Engineering
NAICS code3 codes
  • Surgical Appliance and Supplies Manufacturing339113
  • Medical, Dental, and Hospital Equipment and Supplies Merchant Wholesalers423450
  • Medical Equipment and Supplies Manufacturing3391
SIC code2 codes
  • Orthopedic, Prosthetic & Surgical Appliances & Supplies3842
  • Wholesale-Medical, Dental & Hospital Equipment & Supplies5047
Product category
Surgical Biologics / Orthobiologics
Social media profiles1 record
GTM motion3 records

Each record includes

Type, Description, Source

Revenue model4 records
1Surgical Biologics Products
TypeHardware Sales
Description

Kolosis generates revenue through the sale of surgical biologics products including bone grafts, allograft matrices, and extracellular matrix products. Products are sold to hospitals and surgeons for use in orthopedic, spine, cardiac, and wound care procedures. Revenue is generated through direct sales and distributor relationships with products approved in over 5,800 facilities.

kolosis.com
2Orthobiologics
TypeHardware Sales
Description

Sale of orthobiologic products including Kore Fiber, DBX family (Putty, Mix, Fiber), Summit Matrix, and Prime HD for spinal fusion and orthopedic procedures.

kolosis.com
3Cardiac Surgery Solutions
TypeHardware Sales
Description

Revenue from cardiac surgery products including ATLAS sternal repair matrix and IKON protective barrier for sternal incisions.

kolosis.com
4Surgical Incision Management
TypeHardware Sales
Description

Sale of APEXecm extracellular matrix products for surgical incision management and wound healing applications.

kolosis.com
Marketing channels5 records

Each record includes

Title, Type, Stage, Description, Source

Distribution channels3 records

Each record includes

Title, Type, Scope, Target buyer, Description, Source

Cost components5 values
Supply Chain, Personnel, Marketing or Sales, Operations, Technology or R&D
GTM typeB2B
B2B
Offering typeHardware or Manufacturing
Hardware or Manufacturing
Brand1 of 8 records shown
1DBX
Description

Demineralized bone matrix product family including DBX Putty and DBX Mix, providing moldable consistency with proven osteoinductive potential.

kolosis.com
+7 more records
Core offering1 text field

Kolosis BIO commercializes a portfolio of aseptically processed surgical biologics including demineralized bone matrices (DBX family, Kore Fiber, Prime HD), synthetic bone grafts (Summit Matrix), extracellular matrices for wound healing (APEXecm, Salera), and allograft matrices for cardiac surgery (ATLAS, IKON). All products are sourced exclusively from MTF Biologics and sold to hospitals and surgeons for spine fusion, orthopedic, cardiac surgery, and surgical incision management applications across the US and Canada.

Differentiator
Functional benefit
Problem solved
Quantifiable outcome1 of 4 values shown
  • Kore Fiber demonstrates higher osteoinductivity than commercially available grafts from Medtronic, SeaSpine, and Zimmer Biomet in head-to-head testing
+3 more records
Product overview1 text field

Kolosis BIO is a pure-play surgical biologics company offering a portfolio of biologics products across three categories: Orthobiologics (including Kore Fiber, DBX family products like DBX Putty and DBX Mix, DBX Fiber, Summit Matrix, and Prime HD for bone grafting in spine and orthopedic procedures), Surgical Incision Management (APEXecm with Mini Tile Matrix configuration), and Cardiac Surgery solutions (ATLAS for sternal fusion and IKON for sternal incision protection). All bone graft products are processed by exclusive partner MTF Biologics using proprietary aseptic processing to preserve native matrix proteins and osteoinductive properties.

Product and service9 records
1Kore Fiber
CategoryOrthobiologics
Description

Aseptic-processed pure cortical bone graft combining demineralized cortical fibers with exceptional osteoinductivity data and outstanding handling characteristics, available in moldable putty and compressed strip formats; intended for spine and orthopedic fusion procedures.

2DBX (Putty and Mix)
CategoryOrthobiologics
Description

Demineralized bone matrix family with a scientifically optimized sodium hyaluronate carrier, featuring greater than 95% bone content by volume and validated osteoinductive potential, available in Putty and Mix formulations for spine and orthopedic fusion.

3DBX Fiber
CategoryOrthobiologics
Description

Fiber tissue form addition to the DBX demineralized bone matrix portfolio, processed to provide surgeons with superior handling and osteoinductive potential when addressing complex anatomy and challenging fusion environments.

4Summit Matrix
CategoryOrthobiologics
Description

Synthetic bone graft powered by NanoLift surface technology with nanoscale plate-like topography and biomimetic HCA chemistry that enhances cellular interactions and creates an environment favorable for bone formation, available in Strip and Moldable formulations.

5Prime HD
CategoryOrthobiologics
Description

Pre-hydrated, ready-to-use demineralized bone matrix comprised of elongated demineralized bone particles pre-hydrated in a preservative solution, offering greater than 95% bone by volume with excellent handling properties and verified osteoinductive potential.

6APEXecm
CategorySurgical Incision Management
Description

Next-generation 100% allogenic extracellular matrix featuring Mini Tile Matrix configuration, designed to cover and protect in the natural wound healing environment; comprised of collagen, proteoglycans, and native ECM structural proteins for surgical wound healing.

7ATLAS
CategoryCardiac Surgery
Description

100% demineralized cortical bone allograft engineered for sternal fusion, inserted between sternal edges prior to closure to support stabilization and fusion of the sternum in challenging cardiac surgery patients; available in 1x10 cm strip.

8IKON
CategoryCardiac Surgery
Description

100% allograft matrix from MTF Biologics designed to act as a protective barrier for sternal incisions, using proprietary aseptic processing to retain native extracellular matrix structure; available in Mini Matrix in 80mg and 160mg sizes.

9Salera
CategorySurgical Incision Management
Description

Allograft membrane designed to help optimize surgical outcomes and reduce complications in poor healing patients by supporting surgical wound healing applications.

Scale indicator5 records

Each record includes

Type, Value, Description, Source

Partnership1 partner
Strategic tierCoreTypeStrategic or Co-development Partner
Description

Kolosis BIO exclusively partners with MTF Biologics for all tissue forms. MTF Biologics is a global nonprofit organization headquartered in Edison, New Jersey, with over 30 years of experience in tissue processing. The partnership provides Kolosis access to premium allograft technologies including demineralized bone matrix, cortical fiber allografts, and extracellular matrices. MTF's proprietary aseptic processing preserves biological matrices and osteoinductive properties that terminal sterilization would damage. Kolosis commercializes the full range of MTF tissue forms across orthobiologics, cardiac surgery, and wound care verticals.

Recent move6 records

Each record includes

Date, Type, Title, Description, Source

Expansion highlight5 records

Each record includes

Type, Description

Market position
Competitive moat5 records

Each record includes

Type, Details

Key risks5 records

Each record includes

Headline, Details, Source

Key highlights6 records

Each record includes

Headline, Details, Source

Customer concentration

Classification, Details

Segment4 records

Each record includes

Title, Type, Primary, Description, Pain point addressed, Use case, Source

Ideal customer profile4 records

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

Technology focused
No
API detail
Has APIbool
No

Docs URL, Description

AI maturity
App detail

Has app

Feature5 records

Each record includes

Title, Differentiator, Description, Source

Core technology
Revenue estimate
Valuation estimate
Number of profiles
Profiles17 records

Each record includes

Name, Designation, Designation category, Overview, Profile commentary, Source

No data
No data
Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Kolosis BIO

Surgical Biologics / Orthobiologicskolosis.com

Kolosis BIO is a privately held, pure-play surgical biologics company that commercializes allograft and synthetic bone grafts, extracellular matrices, and cardiac surgery products through an exclusive partnership with MTF Biologics, selling to hospitals and surgeons across spine, orthopedic, cardiac, and wound care procedures.

What Kolosis BIO does

Kolosis BIO is a privately held, pure-play surgical biologics company founded in 2019 and headquartered in Salt Lake City, Utah. The company commercializes a portfolio of allograft and synthetic bone grafts, extracellular matrices, and cardiac surgery products across three categories: orthobiologics, surgical incision management, and cardiac surgery. Its product lineup includes Kore Fiber, the DBX family (Putty, Mix, Fiber), Summit Matrix, Prime HD, APEXecm, ATLAS, and IKON, all sourced through an exclusive partnership with MTF Biologics, a nonprofit tissue processor whose proprietary aseptic processing preserves native collagen architecture, matrix proteins, and osteoinductive potential that terminal sterilization methods would damage.

Kolosis generates revenue by selling surgical biologics to hospitals and surgeons for use in spine fusion, orthopedic bone grafting, cardiac surgery, and wound care procedures. The go-to-market combines an enterprise field sales team with a network of over 400 independent distributors covering all 50 US states and Canada, with products approved in over 5,800 facilities through GPO and IDN contracts accessed via MTF Biologics. The company's 35,000+ fusion procedures over the trailing 12 months reflect established clinical adoption, supported by comparative preclinical data and a sales organization drawn heavily from NuVasive, Orthofix, Medtronic Spine and Biologics, and Globus Medical.

The business model is asset-light distribution of partner-processed tissue, with Kolosis focused on commercial execution, surgeon relationships, and product portfolio expansion rather than tissue processing R&D. Recent strategic activity includes three product launches within roughly 14 months (Summit Matrix in 2025, APEXecm and DBX Fiber in early 2026), entry into cardiac surgery and ECM wound management, and additions to the executive team including a CFO in 2025 and a Southeast AVP in 2026 to support continued national scale.

Kolosis BIO firmographics

Firmographics
Name
Kolosis BIO
Legal name
Kolosis BIO, LLC
Website
https://kolosis.com
Company type
Private
Founded year
2019
Operating status
Operating
Headcount range
11–50 employees
Short description
Kolosis BIO is a privately held, pure-play surgical biologics company that commercializes allograft and synthetic bone grafts, extracellular matrices, and cardiac surgery products through an exclusive partnership with MTF Biologics, selling to hospitals and surgeons across spine, orthopedic, cardiac, and wound care procedures.
Ownership category
akta.pro rank

Kolosis BIO industry classification

Industry
Product category
Surgical Biologics / Orthobiologics
NAICS
Surgical Appliance and Supplies Manufacturing (339113), Medical, Dental, and Hospital Equipment and Supplies Merchant Wholesalers (423450), Medical Equipment and Supplies Manufacturing (3391)
SIC
Orthopedic, Prosthetic & Surgical Appliances & Supplies (3842), Wholesale-Medical, Dental & Hospital Equipment & Supplies (5047)
akta.pro industry
PRIMARYHLAHAEAG
Bone Graft Substitutes & Orthobiologics (Synthetic/Allograft/DBM)
Healthcare & Life Sciences/Medical Devices & Diagnostics/Implants & Prosthetics (Orthopedic/Neuro/Spine/Dental)
SECONDARYHLAAAGAH
Cartilage, Bone & Musculoskeletal Regeneration
Healthcare & Life Sciences/Biotechnology & Biologics/Regenerative Medicine & Tissue Engineering
SECONDARYHLAHALAE
Skin Substitutes & Biologic/Regenerative Wound Therapies (Matrices, Grafts)
Healthcare & Life Sciences/Medical Devices & Diagnostics/Wound Care, Ostomy & Continence Products
SECONDARYHLAAAGAG
Wound Healing & Skin Regeneration (advanced dressings, skin substitutes)
Healthcare & Life Sciences/Biotechnology & Biologics/Regenerative Medicine & Tissue Engineering

Keywords

  • Orthobiologics products
  • Surgical bone grafts
  • Allograft tissue matrices
  • Spine biologics
  • Cardiac surgery matrices

Where Kolosis BIO is headquartered

Location

Headquarters

HQ city
Salt Lake City
HQ country
United States
HQ region
North America

Offices1 record

Markets served

Kolosis BIO business model

Business model
GTM type
B2B
Offering type
Hardware or Manufacturing
Cost components
Supply Chain, Personnel, Marketing or Sales, Operations, Technology or R&D

Revenue model

  1. Surgical Biologics Products: Kolosis generates revenue through the sale of surgical biologics products including bone grafts, allograft matrices, and extracellular matrix products. Products are sold to hospitals and surgeons for use in orthopedic, spine, cardiac, and wound care procedures. Revenue is generated through direct sales and distributor relationships with products approved in over 5,800 facilities.
  2. Orthobiologics: Sale of orthobiologic products including Kore Fiber, DBX family (Putty, Mix, Fiber), Summit Matrix, and Prime HD for spinal fusion and orthopedic procedures.
  3. Cardiac Surgery Solutions: Revenue from cardiac surgery products including ATLAS sternal repair matrix and IKON protective barrier for sternal incisions.
  4. Surgical Incision Management: Sale of APEXecm extracellular matrix products for surgical incision management and wound healing applications.

Go-to-market motion3 records

Distribution channels3 records

Marketing channels5 records

Kolosis BIO product offering

Product offering

Core offering

Kolosis BIO commercializes a portfolio of aseptically processed surgical biologics including demineralized bone matrices (DBX family, Kore Fiber, Prime HD), synthetic bone grafts (Summit Matrix), extracellular matrices for wound healing (APEXecm, Salera), and allograft matrices for cardiac surgery (ATLAS, IKON). All products are sourced exclusively from MTF Biologics and sold to hospitals and surgeons for spine fusion, orthopedic, cardiac surgery, and surgical incision management applications across the US and Canada.

Product overview

Kolosis BIO is a pure-play surgical biologics company offering a portfolio of biologics products across three categories: Orthobiologics (including Kore Fiber, DBX family products like DBX Putty and DBX Mix, DBX Fiber, Summit Matrix, and Prime HD for bone grafting in spine and orthopedic procedures), Surgical Incision Management (APEXecm with Mini Tile Matrix configuration), and Cardiac Surgery solutions (ATLAS for sternal fusion and IKON for sternal incision protection). All bone graft products are processed by exclusive partner MTF Biologics using proprietary aseptic processing to preserve native matrix proteins and osteoinductive properties.

Differentiator

Problem solved

Functional benefit

Brands

  • DBX: Demineralized bone matrix product family including DBX Putty and DBX Mix, providing moldable consistency with proven osteoinductive potential.
  • Kore Fiber
  • Summit Matrix
  • Prime HD
  • APEXecm
  • ATLAS
  • IKON
  • Salera

Products and services

  • Kore Fiber Aseptic-processed pure cortical bone graft combining demineralized cortical fibers with exceptional osteoinductivity data and outstanding handling characteristics, available in moldable putty and compressed strip formats; intended for spine and orthopedic fusion procedures.
  • DBX (Putty and Mix) Demineralized bone matrix family with a scientifically optimized sodium hyaluronate carrier, featuring greater than 95% bone content by volume and validated osteoinductive potential, available in Putty and Mix formulations for spine and orthopedic fusion.
  • DBX Fiber Fiber tissue form addition to the DBX demineralized bone matrix portfolio, processed to provide surgeons with superior handling and osteoinductive potential when addressing complex anatomy and challenging fusion environments.
  • Summit Matrix Synthetic bone graft powered by NanoLift surface technology with nanoscale plate-like topography and biomimetic HCA chemistry that enhances cellular interactions and creates an environment favorable for bone formation, available in Strip and Moldable formulations.
  • Prime HD Pre-hydrated, ready-to-use demineralized bone matrix comprised of elongated demineralized bone particles pre-hydrated in a preservative solution, offering greater than 95% bone by volume with excellent handling properties and verified osteoinductive potential.
  • APEXecm Next-generation 100% allogenic extracellular matrix featuring Mini Tile Matrix configuration, designed to cover and protect in the natural wound healing environment; comprised of collagen, proteoglycans, and native ECM structural proteins for surgical wound healing.
  • ATLAS 100% demineralized cortical bone allograft engineered for sternal fusion, inserted between sternal edges prior to closure to support stabilization and fusion of the sternum in challenging cardiac surgery patients; available in 1x10 cm strip.
  • IKON 100% allograft matrix from MTF Biologics designed to act as a protective barrier for sternal incisions, using proprietary aseptic processing to retain native extracellular matrix structure; available in Mini Matrix in 80mg and 160mg sizes.
  • Salera Allograft membrane designed to help optimize surgical outcomes and reduce complications in poor healing patients by supporting surgical wound healing applications.

Quantifiable outcome

  • Kore Fiber demonstrates higher osteoinductivity than commercially available grafts from Medtronic, SeaSpine, and Zimmer Biomet in head-to-head testing
  • +3 more outcomes

Companies that use Kolosis BIO

Customer profile

Segments4 records

Ideal customer profiles4 records

Kolosis BIO technology and API

Technology

Technology focussed No

API detail

Has API
No
API docs
API detail

Core technology

AI maturity

App detail

Feature5 records

Kolosis BIO partnerships and signals

Strategic signal

Partnerships

One partnership is on record.

  • MTF BiologicscoreStrategic or Co-development PartnerKolosis BIO exclusively partners with MTF Biologics for all tissue forms. MTF Biologics is a global nonprofit organization headquartered in Edison, New Jersey, with over 30 years of experience in tissue processing. The partnership provides Kolosis access to premium allograft technologies including demineralized bone matrix, cortical fiber allografts, and extracellular matrices. MTF's proprietary aseptic processing preserves biological matrices and osteoinductive properties that terminal sterilization would damage. Kolosis commercializes the full range of MTF tissue forms across orthobiologics, cardiac surgery, and wound care verticals.

Scale indicators5 records

Recent moves6 records

Expansion highlights5 records

Kolosis BIO competitors and assessment

Company assessment

Market position

Competitive moat5 records

Key risks5 records

Key highlights6 records

Customer concentration

Kolosis BIO social profiles

Digital presence

Kolosis BIO financial estimates

Financial estimate

Revenue estimate

Valuation estimate

Kolosis BIO leadership team

Management profile

Number of profiles

Profiles17 records

Kolosis BIO funding detail

Funding detail

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

Kolosis BIO M&A and investment

M&A and investment

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Kolosis BIO

What does Kolosis BIO do?

Kolosis BIO commercializes a portfolio of aseptically processed surgical biologics including demineralized bone matrices (DBX family, Kore Fiber, Prime HD), synthetic bone grafts (Summit Matrix), extracellular matrices for wound healing (APEXecm, Salera), and allograft matrices for cardiac surgery (ATLAS, IKON). All products are sourced exclusively from MTF Biologics and sold to hospitals and surgeons for spine fusion, orthopedic, cardiac surgery, and surgical incision management applications across the US and Canada.

Is Kolosis BIO a public or private company?

Kolosis BIO is a private company. It is classified as family owned and is currently operating.

When was Kolosis BIO founded?

Kolosis BIO was founded in 2019. It employs 11 to 50 people.

Where is Kolosis BIO based?

Kolosis BIO is headquartered in Salt Lake City, United States, in the North America region.

How does Kolosis BIO make money?

Four revenue lines are on record. Surgical Biologics Products are the primary driver. The others are orthobiologics, cardiac Surgery Solutions and surgical Incision Management.

Does Kolosis BIO have an API?

No public API is recorded for Kolosis BIO.

What industry is Kolosis BIO in?

Kolosis BIO's product category is Surgical Biologics / Orthobiologics. Its primary akta.pro industry code is HLAHAEAG, Bone Graft Substitutes & Orthobiologics (Synthetic/Allograft/DBM), with a secondary code of HLAAAGAH, Cartilage, Bone & Musculoskeletal Regeneration. Its NAICS code is 339113 and its SIC code is 3842.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales
Live signals
BioSpaceMTF Biologics® and Kolosis BIO® Launch the Latest Addition to the DBX Family: DBX® FiberMTF Biologics and Kolosis BIO announced the launch of DBX Fiber, a new fiber tissue form designed for complex fusion environments in orthopedic and spine procedures, expanding the existing DBX demineralized bone matrix portfolio. The product offers surgeons improved handling and osteoinductive potential through a partnership that strengthens Kolosis's position as a leading pure-play orthobiologics provider in spine and orthopedics. The launch adds to Kolosis's portfolio of surgical biologics including DBX Mix, DBX Putty, Kore Fiber, and Summit Matrix.National TodayMTF Biologics and Kolosis BIO Launch New DBX Fiber ProductMTF Biologics and Kolosis BIO announced the launch of DBX Fiber on March 31, 2026, a next-generation biomaterial product designed to support tissue regeneration and repair. The new product features a fiber-based structure derived from donated human tissue, aiming to enhance handling characteristics and facilitate easier surgical application. The companies plan to showcase the DBX Fiber at the Regenerative Medicine Conference in June 2026.MorningstarMTF Biologics® and Kolosis BIO® Launch the Latest Addition to the DBX Family: DBX® FiberMTF Biologics and Kolosis BIO announced the launch of DBX Fiber, a new fiber tissue form in the DBX demineralized bone matrix family designed to provide surgeons with superior handling and osteoinductive potential for complex fusion procedures. The product expands Kolosis's existing portfolio of surgical biologics, which includes DBX Mix, DBX Putty, Kore Fiber, and Summit Matrix. Both companies described the launch as strengthening their partnership and expanding access to biologic technologies for spine and orthopedic procedures.